Results for this period
Full year1 April 2025 to 31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The principal factors were the accumulation of co-creation project engagements and the early contribution to revenue from DDAIF Innovation Bridge projects in the Life Sciences AI business, the acquisition and integration of アルネッツ in the DX business, and the withdrawal from the business of the U.S. subsidiary and sluggish growth in the acquisition of new projects in the Risk Management business.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025 to 31 March 2026 |
| Net Sales | 7,643 Millions of yen (YoY +25.3%) |
| Operating profit | 739 Millions of yen (YoY +40.1%) |
| Ordinary income | 675 Millions of yen (YoY +24.1%) |
| Profit attributable to owners of the parent | 544 Millions of yen (YoY -2.0%) |
| Net income per share | ¥13.86 |
| Operating Margin | 9.7％ |
| Equity ratio | End of the current fiscal period 39.7％ / End of previous period 45.9％ |
| Total assets | 9,202 Millions of yen |
| Net assets | 3,844 Millions of yen |
| Cash flows from operating activities | 321 Millions of yen |
| Cash flows from investing activities | -2,549 Millions of yen |
| Cash flows from financing activities | 1,335 Millions of yen |
| Cash and cash equivalents at end of period | 1,724 Millions of yen |
| Full-year earnings forecast | Net Sales 7,600 Millions of yen (YoY -0.6%) / Operating profit 300 Millions of yen (YoY -59.4%) / Ordinary income 250 Millions of yen (YoY -63.0%) / Net income 150 Millions of yen (YoY -72.4%) |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Segment revenue | Life Science AI business ¥1,033,237 thousand (YoY +191.4%), Risk management business ¥4,019,943 thousand (YoY -25.2%), DX Business ¥2,590,175 thousand (YoY +598.9%) |
| Segment profit | Life Science AI business ¥-16,185 thousand, Risk management business ¥606,037 thousand (YoY -8.1%), DX Business ¥149,501 thousand (YoY +49.6%) |
| Depreciation and amortization | ¥375,957 thousand |
| Impairment loss | ¥14,212 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥228 thousand, Gain on reversal of subscription rights to shares ¥62,654 thousand, Gain on sale of investment securities ¥2,156 thousand / Extraordinary loss Loss on sale of fixed assets ¥8,167 thousand, Loss on Disposal of Fixed Assets ¥917 thousand, Impairment Losses ¥14,212 thousand, Loss on the reorganization of overseas subsidiaries ¥51,451 thousand, Other ¥226 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社アルネッツ / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | From the fiscal year ending March 2027, the business intelligence and professional support businesses will be transferred from the DX business to the Risk Management business, and the reporting segment classification will be changed so that the DX business consists solely of アルネッツ. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 39,412,362 Shares |
| Treasury Shares at Period-End | 230,859 Shares |
| Factors Behind Changes in Business Performance | The principal factors were the accumulation of co-creation project engagements and the early contribution to revenue from DDAIF Innovation Bridge projects in the Life Sciences AI business, the acquisition and integration of アルネッツ in the DX business, and the withdrawal from the business of the U.S. subsidiary and sluggish growth in the acquisition of new projects in the Risk Management business. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased in the Life Sciences AI business due to the accumulation of co-creation project engagements and the early contribution to revenue from DDAIF Innovation Bridge projects. Revenue in the DX business increased substantially following the acquisition and integration of 株式会社アルネッツ. Meanwhile, revenue in the Risk Management business declined due in part to the withdrawal from the business of its U.S. subsidiary. The decline in net income was primarily attributable to the reversal effect of the return of deferred income tax adjustments recognized in the previous fiscal year as a result of tax effects.